论文部分内容阅读
为评价头孢匹胺治疗细菌性感染的疗效和安全性 ,以头孢匹胺与头孢哌酮随机对照治疗 12 7例患者 ,主要为下呼吸道、尿路等细菌性感染。两药剂量均为每日 2～ 4g,疗程 7～ 14d。头孢匹胺组 6 3例 ,头孢哌酮组 6 4例 ,两组有效率分别为 87.3%和 90 .6 % ,痊愈率为 5 5 .6 %和 6 0 .9% ,细菌清除率为 84.7%和 89.7%。两药不良反应均轻微且呈一过性 ,发生率为 7.0 %和 4.3% ,主要为皮疹等。两组比较 ,上述差异均无显著性 (P>0 .0 5 )。本研究提示 ,头孢匹胺每日 2～ 4g,疗程 7～ 14d治疗常见细菌性感染的疗效和安全性与头孢哌酮相仿。
To evaluate the efficacy and safety of cefpiramide in the treatment of bacterial infections, a randomized controlled trial of cefpiramil and cefoperazone was performed in 127 patients, mainly bacterial infections such as lower respiratory tract and urinary tract. Two doses are daily 2 ~ 4g, treatment 7 ~ 14d. Cefpiramide group 63 cases, cefoperazone group 64 cases, the two groups were 87.3% and 90.6%, the cure rate was 55.6% and 60.9%, the bacterial clearance rate was 84.7 % And 89.7%. Adverse reactions to both drugs were mild and transient, the incidence was 7.0% and 4.3%, mainly rashes and so on. There was no significant difference between the two groups (P> 0.05). The study suggests that cefpiramide daily 2 ~ 4g, 7 ~ 14d treatment of common bacterial infections efficacy and safety and cefoperazone similar.